

Rome, Italy | May 29-30, 2015

FACULTY

Carlo Albera, Torino
Massimo Amicosante, Roma
Elena Bargagli, Siena
Martina Bonifazi, Ancona
Zea Borok, Los Angeles – CA (USA)
Mark L. Brantly, Gainesville – FL (USA)
Mathieu Cellier, Laval (CDN)
Elena Corradini, Modena
Ulrich Costabel, Essen (DE)
Bruno Crestani, Paris (FR)
Donato Di Piero, Roma
Marco L. Dottorini, Perugia
Sergio Alfonso Harari, Milano
Fabrizio Luppi, Modena
Joachim Müller Quernheim, Freiburg (DE)
Gregorino Paone, Roma

Venerino Poletti, Forlì
Ermanno Puxeddu, Roma
Alberto Ricci, Roma
Paola Rottoli, Siena
Cesare Saltini, Gainesville – FL (USA)
Alessandro Sanduzzi Zamparelli, Napoli
Federica Carla Sangiuolo, Roma
Alfredo Sebastiani, Roma
Silvia Svegliati Baroni, Ancona
Sara Tomassetti, Forlì
Dominique Valeyre, Paris (FR)
Coline van Moorsel, Nieuwegein/Utrecht (NL)
Francesco Varone, Roma
Liana Veneziano, Roma
Maurizio Zompatori, Bologna

A I P O
ASSOCIAZIONE
ITALIANA
PNEUMOLOGI
OSPEDALIERI

PROVIDER NAZIONALE n° 5079

SOCIETÀ SCIENTIFICA CERTIFICATA UNI EN ISO 9001:2008
PER LA PROGETTAZIONE, GESTIONE ED EROGAZIONE DI
EVENTI FORMATIVI E CONGRESSI NELL'AMBITO SANITARIO
E NELL'EDUCAZIONE CONTINUA IN MEDICINA (IAF37)

Certificato TÜV Italia N. 501004504 - Rev. 05



AIPO DICHIARA CHE LE ATTIVITÀ ECM SONO SVOLTE IN MANIERA AUTONOMA ASSUMENDOSI LA RESPONSABILITÀ
DEI CONTENUTI FORMATIVI, DELLA QUALITÀ SCIENTIFICA E DELLA CORRETTEZZA ETICA DI DETTE ATTIVITÀ

CHAIRMEN

Venerino Poletti
U.O. Pneumologia
Ospedale G.B. Morgagni - L. Pierantoni, Forlì
Cesare Saltini
University of Florida, Gainesville - FL (USA)

SCIENTIFIC COMMITTEE

Gabriella Pezzuto, Roma
Ermanno Puxeddu, Roma
Alfredo Sebastiani, Roma
Francesco Varone, Roma

CONFERENCE VENUE

Palazzo delle Esposizioni
Via Milano, 9 - Roma

CONTINUING MEDICAL EDUCATION (CME)

The Course is accredited by AIPO-Italian Association of Hospital Pulmonologists
to provide Continuing Medical Education (CME) for Italian physicians.
Educational Objective 2: Guidelines, Protocols, Procedures
Provider Number 5079
Course ID Code: 121578
Participants: 70
CME Credits: 12

Disciplines: Pulmonology, Geriatrics, Internal Medicine, Thoracic Surgery, Clinical Pathology, Pathological Anatomy, Radiodiagnostics.

To certificate CME Credits participants must attend 100% of the Scientific Program

OFFICIAL LANGUAGE ENGLISH

ORGANIZING SECRETARIAT

A I P O
RICERCHE

Via Antonio da Recanate, 2 – 20124 MILANO
Tel. +39 02 36590350 – Fax +39 02 67382337
segreteria@aiporicerche.it
www.aiporicerche.it

aiponet

Dal 2004 al servizio della Pneumologia Italiana
aiposegreteria@aiporicerche.it
www.aiponet.it

Unrestricted grant of



A I P O
ASSOCIAZIONE
ITALIANA
PNEUMOLOGI
OSPEDALIERI

IDIOPATHIC PULMONARY FIBROSIS THE MISSING LINK

Rome, Italy | May 29-30, 2015
Palazzo delle Esposizioni

Chairmen: V. Poletti, C. Saltini

IDIOPATHIC PULMONARY FIBROSIS

THE MISSING LINK

Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and limited to the lungs. It is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis.

The pathogenesis of IPF is still unclear and a complex series of pathological events, many of which shared by other forms of pulmonary and systemic idiopathic fibrosing disorders, have been shown to be involved in the development of the typical Usual Interstitial Pneumonia (UIP) pulmonary lesions. Among them, increased local production of reactive oxygen species, abnormal wound healing in response to multiple microscopic injury, epithelial activation and hyperplasia, presence of cellular de-differentiation and epithelial to mesenchymal transition, imbalance in angiogenetic/angiostatic process, unusual proliferation of mesenchymal cells with matrix deposition, disruption of coagulation pathway and increase of capillary permeability. On the research side, a growing number of studies have been aimed at the identification of the susceptibility gene(s) or the environmental exposures that could drive the pathogenic process of IPF: On the other hand, several controlled clinical trials have been carried out and new effective agents are - or will be soon - available for the treatment of IPF affected patients. In addition, considerable efforts have been made by scientific societies and associations to improve upon diagnostic and treatment standards for IPF patients and a simpler approach to the diagnosis have emerged from these efforts. Most importantly, interest in IPF basic and clinical research alike is continuously growing.

The purpose of this meeting is to provide an update on recent advances in the field of the basic and clinical science of IPF: The most recent advancements in the understanding of the biological processes responsible for IPF pathogenesis will be critically reviewed and the most recent criteria for diagnosing and treating the disease, both in research and real life settings, will be discussed.

Venerino Poletti, Cesare Saltini

Rome, Italy | May 29-30, 2015

PROGRAM

FRIDAY, May 29th

09.30-10.00 *Welcome address*
Introduction *C. Saltini*

SESSION 1

OXIDATIVE STRESS & FIBROSIS

Chair: P. Rottoli

10.00-10.30 *Lecture* : hereditary hemochromatosis: a disease model *E. Corradini*
10.30-11.00 Oxidants, antioxidants and fibrosis *E. Bargagli*
11.00-11.30 EMT and fibrosis *Z. Borok*
11.30-12.30 Discussion *M. Bonifazi, G. Paone*

SESSION 2

BIOLOGY OF IRON

Chair: E. Puxeddu

13.30-14.00 The “BCG gene” *M. Cellier*
14.00-14.30 Insights from familial IPF *C. van Moorsel*
14.30-15.00 α-1- AT misfolding in macrophages activates fibrosis and UPR related genes *M. Brantly*
15.00-15.30 Discussion *E. Puxeddu, A. Ricci*

SESSION 3

GENES AND MECHANISMS OF FIBROSIS

Chair: A. Sanduzzi Zamparelli, F. Sangiuolo

16.00-16.30 Macrophage phenotype in lung disease *J. Müller Querneim*
16.30-17.00 The PDGF, WINT WIF TGFβ path *S. Svegliati Baroni*
17.00-17.30 Alveolar macrophage transcriptome in IPF *C. Saltini*
17.30-18.00 Discussion *M. Amicosante, D. Di Pierro, L. Veneziano*

SATURDAY, May 30th

SESSION 4
DIAGNOSIS OF PULMONARY FIBROSIS, WHAT’S NEW?
Chair: C. Albera

09.00-09.30 Classification a clinical appraisal *D. Valeyre*
09.30-10.00 Confident HRCT? *M. Zompatori*
10.00-10.30 Genetic diagnostic markers *B. Crestani*
10.30-11.00 Determinants of disease course *E. Puxeddu*
11.00-11.30 Discussion *M. Dottorini, S. Tomassetti, F. Varone*

SESSION 5
TREATMENT
Chair: G. Paone

12.00-12.30 Out of proportion hypertension *S. A. Harari*
12.30-13.00 Pirfenidone, from trial to real life *V. Poletti*
13.00-13.30 Do subgroups of patients respond differently to current IPF therapy? *U. Costabel*
13.30-14.30 Discussion *F. Luppi, A. Sebastiani*
14.30-15.00 Closing round table
From the bench to the bedside *V. Poletti, C. Saltini, A. Sebastiani*